SDGR Overview

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is21.83 USD with a low forecast of 18.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Schrodinger Inc revenue for the last quarter amounts to 58.59M USD, decreased -1.62

Schrodinger Inc. EPS for the last quarter amounts to -0.81 USD, decreased -1.22

Schrodinger Inc (SDGR) has 850 emplpoyees as of May 28 2026.

Today SDGR has the market capitalization of 989.30M USD.